Wikidata:Database reports/Constraint violations/P3354
Jump to navigation
Jump to search
Constraint violations report for positive therapeutic predictor for (Discussion, uses, items, changes, related properties): the presence of the genetic variant helps to predict response to a treatment
Data time stamp: (UTC) — Items processed: 576
The report is generated based on the settings on Property:P3354#P2302.
Updates overwrite this page. Some may already be fixed since the last update: check RecentChangesLinked.
When incremental dumps and the bot work as planned, items fixed before 07:00 UTC disappear in the next update. The report is not updated if only the item count changes.
The report can include false positives. There is no need to "fix" them.
Data time stamp: (UTC) — Items processed: 576
The report is generated based on the settings on Property:P3354#P2302.
Updates overwrite this page. Some may already be fixed since the last update: check RecentChangesLinked.
When incremental dumps and the bot work as planned, items fixed before 07:00 UTC disappear in the next update. The report is not updated if only the item count changes.
The report can include false positives. There is no need to "fix" them.
"Scope" violations
[edit]Violations count: 0
"Type sequence variant (Q15304597)" violations
[edit]Violations count: 82
- ERBB2 Amplification (Q27908387): Transcript Amplification (Q27907091)
- EGFR VIII (Q28371264): disruptive inframe deletion (Q42866969)
- EGFR V769_770insASV (Q28371649): Insertion (Q32937968)
- ERBB2 M774DELINSWLV (Q28371692): inframe indel (Q42866966)
- NPM1 W288FS (Q28381458): Frameshift Elongation (Q28381989)
- FLT3 TKD MUTATION (Q28381821): Nonsynonymous Variant (Q27905684)
- EGFR Copy Number Variation (Q28382120): Copy Number Change (Q28381984)
- ABCB1 I1145I (Q28421333): Synonymous Variant (Q28419125)
- MGMT RS16906252 (Q28422524): Synonymous Variant (Q28419125)
- ETS2 RS461155 (Q28423012): Synonymous Variant (Q28419125)
- KIT RS3733542 (Q28423248): Synonymous Variant (Q28419125)
- HSPH1 T17 DELETION (Q28423257): Short Tandem Repeat Variation (Q28419126)
- PMS2 K706FS*19 (Q28423265): Minus 1 Frameshift Variant (Q28419135)
- TP53 Wildtype (Q28439291): wild type (Q128723)
- CCND1 Amplification (Q28444926): Transcript Amplification (Q27907091)
- AURKA AMPLIFICATION (Q28444955): Transcript Amplification (Q27907091)
- CCNE1 Amplification (Q28444962): Transcript Amplification (Q27907091)
- EGFR Amplification (Q28444964): Transcript Amplification (Q27907091)
- PIK3CA Amplification (Q28444974): Transcript Amplification (Q27907091)
- PTEN Deletion (Q28444975): Transcript Ablation (Q28381986)
- GSTP1 DELETION (Q28444988): Transcript Ablation (Q28381986)
- FGFR1 Amplification (Q28444992): Transcript Amplification (Q27907091)
- MET Amplification (Q28444994): Transcript Amplification (Q27907091)
- MYCN Amplification (Q28445010): Transcript Amplification (Q27907091)
- TOP1 AMPLIFICATION (Q28445062): Transcript Amplification (Q27907091)
- CDK4 AMPLIFICATION (Q28445152): Transcript Amplification (Q27907091)
- CDKN2B LOSS (Q28445154): Transcript Ablation (Q28381986)
- RICTOR AMPLIFICATION (Q28445159): Transcript Amplification (Q27907091)
- RAF1 AMPLIFICATION (Q28445164): Transcript Amplification (Q27907091)
- KRAS Amplification (Q28445165): Transcript Amplification (Q27907091)
- FGFR2 Amplification (Q28445180): Transcript Amplification (Q27907091)
- FGF3 AMPLIFICATION (Q28445181): Transcript Amplification (Q27907091)
- AKT2 Amplification (Q28445184): Transcript Amplification (Q27907091)
- SMARCB1 DELETION (Q28445214): Transcript Ablation (Q28381986)
- PDGFRA Amplification (Q28445223): Transcript Amplification (Q27907091)
- NTRK1 Amplification (Q29938785): Transcript Amplification (Q27907091)
- NTRK3 Amplification (Q29938787): Transcript Amplification (Q27907091)
- RAD50 L1237F (Q44844631):
- ERRFI1 E384Ter (Q44844639):
- EGFR V834I (Q44847119):
- BARD1 LOSS-OF-FUNCTION (Q50092860):
- ALK ALK FUSION (Q50092864):
- BRAF G496A (Q50092865):
- BRAF intron 9 rearrangement (Q50092874):
- BRAF intron 10 rearrangement (Q50092876):
- RASA1 LOSS-OF-FUNCTION (Q50887761):
- EGFR L861 (Q56240933):
- FGFR2 FGFR2 mutations (Q56240986):
- BAP1 ALTERNATIVE TRANSCRIPT (ATI) (Q56240987):
- NRG1 Fusion (Q56240996):
- EGFR Rare Mutation (Q56241007):
- JAK2 F694L (Q60243481):
- PIK3CA Wildtype (Q60934773): wild type (Q128723)
- KIT T417_D419delinsY (Q66084575):
- KIT F506_F508DUP (Q66084576):
- KIT K484_G487DEL (Q66084577):
- PDGFRA Exon 18 Mutation (Q66084578):
- KIT Exon 13 Mutation (Q66084579):
- BRAF Exon 15 Mutation (Q66084580):
- KIT WILDTYPE (Q66084581): wild type (Q128723)
- CDKN2A Mutation (Q66084587):
- MET R1004G (Q72011747):
- BRAF N486_P490del (Q76177655):
- ABL2 Fusion (Q79419373):
- PARP1 OVEREXPRESSION (Q79419402):
- ABL1 ABL1-RCSD (Q79419469):
- FGFR3 Mutations (Q79419509):
- PRPS1 L191F (Q86217709):
- PRPS1 N144S (Q92591664):
- PDGFRA Overexpression (Q96008277):
- PDGFRB Overexpression (Q96008315):
- SMARCA4 LOSS (Q98713507):
- BRCA2 K3326* (Q98713516):
- FLT3 Y842C (Q98713568):
- EGFR M766_A767insASV (Q105669004):
- NTRK1 LMNA::NTRK1 e2-e10 (Q106942743):
- PDGFRA Mutation (Q106942752):
- KDR R1032Q (Q107522017):
- ALK I1171T (Q107522020):
- FLCN c.1285dupC (Q111015485):
- SLC29A1 Overexpression (Q111015486):
- IGF1R Overexpression (Q111399004):
Types statistics
[edit]
"Entity types" violations
[edit]Violations count: 0
"Value type chemical compound (Q11173)" violations
[edit]Violations count: 161
- BRAF V600E (Q21851559): Dabrafenib / Trametinib combination therapy (Q38160427): combination therapy (Q1304270)
- BRAF V600E (Q21851559): Vemurafenib / Gefitinib / Cetuximab combination therapy (Q39136135): combination therapy (Q1304270)
- BRAF V600E (Q21851559): Vemurafenib / Panitumumab combination therapy (Q38160432): combination therapy (Q1304270)
- BRAF V600E (Q21851559): Vemurafenib / Panitumumab combination therapy (Q38160432): combination therapy (Q1304270)
- BRAF V600E (Q21851559): Dabrafenib / Trametinib combination therapy (Q38160427): combination therapy (Q1304270)
- BRAF V600E (Q21851559): vemurafenib / cobimetinib fumarate combination therapy (Q44844037): combination therapy (Q1304270)
- BRAF V600E (Q21851559): trametinib / vemurafenib / dabrafenib combination therapy (Q56240694): combination therapy (Q1304270)
- BRAF V600E (Q21851559): Irinotecan / Vemurafenib / Cetuximab combination therapy (Q43387526): combination therapy (Q1304270)
- BRAF V600E (Q21851559): Dabrafenib / Trametinib combination therapy (Q38160427): combination therapy (Q1304270)
- BRAF V600E (Q21851559): Panitumumab / Dabrafenib / Trametinib combination therapy (Q38160409): combination therapy (Q1304270)
- BRAF V600E (Q21851559): Panitumumab / Trametinib combination therapy (Q38160429): combination therapy (Q1304270)
- BRAF V600E (Q21851559): Sorafenib / Panitumumab combination therapy (Q41799607): combination therapy (Q1304270)
- BRAF V600E (Q21851559): irinotecan / Panitumumab / vemurafenib combination therapy (Q56240613): combination therapy (Q1304270)
- BRAF V600E (Q21851559): Dabrafenib / Trametinib combination therapy (Q38160427): combination therapy (Q1304270)
- BRAF V600E (Q21851559): Capecitabine / Vemurafenib / Bevacizumab combination therapy (Q38836200): combination therapy (Q1304270)
- BRAF V600E (Q21851559): Irinotecan / Vemurafenib / Cetuximab combination therapy (Q43387526): combination therapy (Q1304270)
- BRAF V600E (Q21851559): erlotinib / vemurafenib combination therapy (Q98711646): combination therapy (Q1304270)
- BRAF V600E (Q21851559): Pertuzumab / vemurafenib combination therapy (Q104538361): combination therapy (Q1304270)
- BRAF V600E (Q21851559): Dabrafenib / Trametinib combination therapy (Q38160427): combination therapy (Q1304270)
- BRAF V600E (Q21851559): cetuximab / encorafenib / binimetinib combination therapy (Q104538384): combination therapy (Q1304270)
- BRAF V600E (Q21851559): Dabrafenib / Trametinib combination therapy (Q38160427): combination therapy (Q1304270)
- BRAF V600E (Q21851559): Dabrafenib / Trametinib combination therapy (Q38160427): combination therapy (Q1304270)
- BRAF V600E (Q21851559): Dabrafenib / Trametinib combination therapy (Q38160427): combination therapy (Q1304270)
- BRAF V600E (Q21851559): cetuximab / encorafenib / binimetinib combination therapy (Q104538384): combination therapy (Q1304270)
- BRAF V600E (Q21851559): Cetuximab / encorafenib combination therapy (Q56240617): combination therapy (Q1304270)
- EGFR T790M (Q25100112): pemetrexed / erlotinib combination therapy (Q58643642): combination therapy (Q1304270)
- PML PML::RARA (Q27908385): tretinoin / ortho-arsenite ion combination therapy (Q46738161): combination therapy (Q1304270)
- ERBB2 Amplification (Q27908387): Trastuzumab / Lapatinib combination therapy (Q38160367): combination therapy (Q1304270)
- ERBB2 Amplification (Q27908387): Trastuzumab / Lapatinib combination therapy (Q38160367): combination therapy (Q1304270)
- ERBB2 Amplification (Q27908387): Trastuzumab / Lapatinib combination therapy (Q38160367): combination therapy (Q1304270)
- ERBB2 Amplification (Q27908387): afatinib / Trastuzumab combination therapy (Q58645247): combination therapy (Q1304270)
- ERBB2 Amplification (Q27908387): Trastuzumab / irinotecan combination therapy (Q58645257): combination therapy (Q1304270)
- ERBB2 Amplification (Q27908387): docetaxel trihydrate / Trastuzumab / Pertuzumab combination therapy (Q58645264): combination therapy (Q1304270)
- ERBB2 Amplification (Q27908387): capecitabine / lapatinib combination therapy (Q58645278): combination therapy (Q1304270)
- ERBB2 Amplification (Q27908387): capecitabine / Trastuzumab combination therapy (Q58645282): combination therapy (Q1304270)
- ERBB2 Amplification (Q27908387): docetaxel trihydrate / Trastuzumab / Pertuzumab combination therapy (Q58645264): combination therapy (Q1304270)
- ERBB2 Amplification (Q27908387): Trastuzumab / palbociclib combination therapy (Q58645304): combination therapy (Q1304270)
- ERBB2 Amplification (Q27908387): Pertuzumab / Trastuzumab combination therapy (Q50092193): combination therapy (Q1304270)
- ERBB2 Amplification (Q27908387): Pertuzumab / Trastuzumab combination therapy (Q50092193): combination therapy (Q1304270)
- ERBB2 Amplification (Q27908387): Pertuzumab / Trastuzumab combination therapy (Q50092193): combination therapy (Q1304270)
- ERBB2 Amplification (Q27908387): Pertuzumab / Trastuzumab combination therapy (Q50092193): combination therapy (Q1304270)
- ERBB2 Amplification (Q27908387): Pertuzumab / Trastuzumab combination therapy (Q50092193): combination therapy (Q1304270)
- ERBB2 Amplification (Q27908387): Pertuzumab / Trastuzumab combination therapy (Q50092193): combination therapy (Q1304270)
- ERBB2 Amplification (Q27908387): Trastuzumab / Lapatinib combination therapy (Q38160367): combination therapy (Q1304270)
- ERBB2 Amplification (Q27908387): Pertuzumab / Trastuzumab combination therapy (Q50092193): combination therapy (Q1304270)
- ERBB2 Amplification (Q27908387): Pertuzumab / Trastuzumab combination therapy (Q50092193): combination therapy (Q1304270)
- ERBB2 L755S (Q28370977): lapatinib / neratinib / Trastuzumab combination therapy (Q44732174): combination therapy (Q1304270)
- ERBB2 V777L (Q28370984): lapatinib / neratinib / Trastuzumab combination therapy (Q44732174): combination therapy (Q1304270)
- ERBB2 V842I (Q28370985): lapatinib / neratinib / Trastuzumab combination therapy (Q44732174): combination therapy (Q1304270)
- KRAS G12C (Q28371011): selumetinib / docetaxel trihydrate combination therapy (Q44738713): combination therapy (Q1304270)
- KRAS G12C (Q28371011): selumetinib / dactolisib combination therapy (Q44738723): combination therapy (Q1304270)
- PIK3CA E542K (Q28371029): apitolisib (Q27074481): type of chemical entity (Q113145171), phosphoinositide-3 kinase inhibitor (Q7187512)
- PIK3CA E545K (Q28371031): apitolisib (Q27074481): type of chemical entity (Q113145171), phosphoinositide-3 kinase inhibitor (Q7187512)
- PIK3CA E545K (Q28371031): pictilisib / cisplatin combination therapy (Q105024843): combination therapy (Q1304270)
- PIK3CA H1047R (Q28371034): Fulvestrant / everolimus combination therapy (Q44843816): combination therapy (Q1304270)
- TP53 R273C (Q28371043): etoposide / mitomycin / cisplatin combination therapy (Q60242592): combination therapy (Q1304270)
- DDR2 S768R (Q28371064): erlotinib / dasatinib monohydrate combination therapy (Q44843688): combination therapy (Q1304270)
- ATM Underexpression (Q28371091): paclitaxel / olaparib combination therapy (Q98713028): combination therapy (Q1304270)
- TP53 Deleterious Mutation (Q28371191): adjuvant therapy (Q2481887): medical treatment (Q179661)
- ERCC2 K751Q (Q28371219): carboplatin / paclitaxel combination therapy (Q112114652): combination therapy (Q1304270)
- RET KIF5B::RET (Q28371227): vandetanib / everolimus combination therapy (Q44843787): combination therapy (Q1304270)
- EGFR Exon 18 Overexpression (Q28371334): erlotinib / Bevacizumab combination therapy (Q44843882): combination therapy (Q1304270)
- ERBB2 M774INSAYVM (Q28371378): Sirolimus / afatinib combination therapy (Q44843919): combination therapy (Q1304270)
- ERBB2 M774INSAYVM (Q28371378): Sirolimus / afatinib combination therapy (Q44843919): combination therapy (Q1304270)
- NRAS Q61K (Q28371390): everolimus / binimetinib combination therapy (Q44843927): combination therapy (Q1304270)
- EGFR P753S (Q28371422): Cetuximab / Sirolimus combination therapy (Q38160413): combination therapy (Q1304270)
- ERBB2 L866M (Q28371453): lapatinib / neratinib / Trastuzumab combination therapy (Q44732174): combination therapy (Q1304270)
- ERBB2 S310F/Y (Q28371454): lapatinib / neratinib / Trastuzumab combination therapy (Q44732174): combination therapy (Q1304270)
- PDGFRB EBF1::PDGFRB (Q28371491): imatinib / chemotherapy combination therapy (Q104538859): combination therapy (Q1304270)
- BRAF V600K (Q28371521): Dabrafenib / Trametinib combination therapy (Q38160427): combination therapy (Q1304270)
- BRAF V600K (Q28371521): Dabrafenib / Trametinib combination therapy (Q38160427): combination therapy (Q1304270)
- BRAF KIAA1549::BRAF (Q28371571): trametinib / everolimus combination therapy (Q104538926): combination therapy (Q1304270)
- BRAF KIAA1549::BRAF (Q28371571): sorafenib / temsirolimus / Bevacizumab combination therapy (Q44844082): combination therapy (Q1304270)
- NPM1 W288FS (Q28381458): etoposide / cytarabine / daunorubicin combination therapy (Q107671225): combination therapy (Q1304270)
- MTOR P2213S (Q28422190): azd-5363 / ly-294002 combination therapy (Q44843798): combination therapy (Q1304270)
- WEE1 RS3910384 (Q28422466): gemcitabine / platinum combination therapy (Q44843834): combination therapy (Q1304270)
- ETS2 RS461155 (Q28423012): cisplatin / paclitaxel combination therapy (Q44843943): combination therapy (Q1304270)
- HSPH1 T17 DELETION (Q28423257): fluorouracil / Oxaliplatin combination therapy (Q44843973): combination therapy (Q1304270)
- PTEN V317FS (Q28423309): ci-1040 / MK-2206 combination therapy (Q44844070): combination therapy (Q1304270)
- TP53 Wildtype (Q28439291): Cetuximab / capecitabine / Oxaliplatin combination therapy (Q58645227): combination therapy (Q1304270)
- TP53 Wildtype (Q28439291): chemotherapy (Q974135): treatment of cancer (Q2575340), chemiotherapy (Q3252988)
- TP53 Wildtype (Q28439291): adjuvant therapy (Q2481887): medical treatment (Q179661)
- CCND1 Amplification (Q28444926): carboplatin / sorafenib / paclitaxel combination therapy (Q112114533): combination therapy (Q1304270)
- GATA2 EXPRESSION (Q28444931): fasudil / bortezomib combination therapy (Q44738679): combination therapy (Q1304270)
- AURKA EXPRESSION (Q28444946): fluorouracil / cisplatin combination therapy (Q44843692): combination therapy (Q1304270)
- AURKA AMPLIFICATION (Q28444955): alisertib / cisplatin combination therapy (Q44843706): combination therapy (Q1304270)
- BRCA1 Mutation (Q28444960): cediranib / olaparib combination therapy (Q44843714): combination therapy (Q1304270)
- BRCA2 Mutation (Q28444961): cediranib / olaparib combination therapy (Q44843714): combination therapy (Q1304270)
- CCNE1 Amplification (Q28444962): dinaciclib / MK-2206 combination therapy (Q44843716): combination therapy (Q1304270)
- EGFR Overexpression (Q28444966): docetaxel trihydrate / Cetuximab combination therapy (Q44843818): combination therapy (Q1304270)
- NRAS Mutation (Q28444972): trametinib / docetaxel trihydrate combination therapy (Q58644707): combination therapy (Q1304270)
- NRAS Mutation (Q28444972): trametinib / metformin combination therapy (Q58644710): combination therapy (Q1304270)
- NRAS Mutation (Q28444972): ribociclib / binimetinib combination therapy (Q58644721): combination therapy (Q1304270)
- PTEN Loss (Q28444976): carboplatin / paclitaxel / buparlisib combination therapy (Q112114628): combination therapy (Q1304270)
- TP53 Mutation (Q28444982): doxorubicin / etoposide / cisplatin combination therapy (Q66690025): combination therapy (Q1304270)
- TP53 Mutation (Q28444982): chemotherapy (Q974135): treatment of cancer (Q2575340), chemiotherapy (Q3252988)
- MET Amplification (Q28444994): Crizotinib / Vemurafenib combination therapy (Q38160428): combination therapy (Q1304270)
- MET Amplification (Q28444994): crizotinib / Cetuximab combination therapy (Q58645046): combination therapy (Q1304270)
- CD274 Expression (Q28444998): Ipilimumab / nivolumab combination therapy (Q58645094): combination therapy (Q1304270)
- MTOR MUTATION (Q28444999): Everolimus / Pazopanib combination therapy (Q38160418): combination therapy (Q1304270)
- ERBB3 Overexpression (Q28445003): afatinib / selumetinib combination therapy (Q58645166): combination therapy (Q1304270)
- MYCN Amplification (Q28445010): panobinostat / JQ1 combination therapy (Q106942323): combination therapy (Q1304270)
- VEGFA Decreased Peri-therapeutic Expression (Q28445035): Bevacizumab / fluorouracil / irinotecan / levoleucovorin combination therapy (Q44843837): combination therapy (Q1304270)
- KRAS Mutation (Q28445037): dasatinib monohydrate / Cetuximab combination therapy (Q44843842): combination therapy (Q1304270)
- KRAS Mutation (Q28445037): refametinib / sorafenib combination therapy (Q58645543): combination therapy (Q1304270)
- KRAS Mutation (Q28445037): pemetrexed / trametinib / docetaxel trihydrate combination therapy (Q58645559): combination therapy (Q1304270)
- KRAS Mutation (Q28445037): binimetinib / palbociclib combination therapy (Q58645573): combination therapy (Q1304270)
- KRAS Mutation (Q28445037): afatinib / trametinib combination therapy (Q58645515): combination therapy (Q1304270)
- KRAS Mutation (Q28445037): afatinib / trametinib combination therapy (Q58645515): combination therapy (Q1304270)
- SMARCA4 UNDEREXPRESSION (Q28445048): Vinorelbine / cisplatin combination therapy (Q44843859): combination therapy (Q1304270)
- BIRC5 NUCLEAR EXPRESSION (Q28445060): platinum / taxane combination therapy (Q44843873): combination therapy (Q1304270)
- TOP1 AMPLIFICATION (Q28445062): irinotecan (Q412197): type of chemical entity (Q113145171), Irinotecan (Q26989371)
- CDKN1B EXPRESSION (Q28445063): fluorouracil / cisplatin combination therapy (Q44843692): combination therapy (Q1304270)
- ZEB1 Expression (Q28445066): Salinomycin / doxorubicin combination therapy (Q44843885): combination therapy (Q1304270)
- TOP1 EXPRESSION (Q28445075): irinotecan (Q412197): type of chemical entity (Q113145171), Irinotecan (Q26989371)
- TOP1 EXPRESSION (Q28445075): carboplatin / topotecan / cyclophosphamide hydrate combination therapy (Q112114756): combination therapy (Q1304270)
- KIT MUTATION (Q28445077): imatinib / pictilisib combination therapy (Q58645769): combination therapy (Q1304270)
- BRCA1 Underexpression (Q28445090): platinum / taxane combination therapy (Q44843873): combination therapy (Q1304270)
- CDKN2A Loss (Q28445153): palbociclib / letrozole combination therapy (Q44738667): combination therapy (Q1304270)
- NF1 Mutation (Q28445162): Sirolimus / pd-0325901 combination therapy (Q44844052): combination therapy (Q1304270)
- RAF1 AMPLIFICATION (Q28445164): carboplatin / sorafenib / paclitaxel combination therapy (Q112114533): combination therapy (Q1304270)
- KRAS Amplification (Q28445165): carboplatin / sorafenib / docetaxel trihydrate combination therapy (Q110648154): combination therapy (Q1304270)
- CDK6 OVEREXPRESSION (Q28445172): Fulvestrant / palbociclib combination therapy (Q44844065): combination therapy (Q1304270)
- ESR1 Overexpression (Q28445174): palbociclib / letrozole combination therapy (Q44738667): combination therapy (Q1304270)
- AKT2 Amplification (Q28445184): vandetanib / everolimus combination therapy (Q44843787): combination therapy (Q1304270)
- ERBB2 Mutation (Q28445204): Pertuzumab / Trastuzumab combination therapy (Q50092193): combination therapy (Q1304270)
- BRAF V600 (Q28531477): Dabrafenib / Trametinib combination therapy (Q38160427): combination therapy (Q1304270)
- BRAF V600 (Q28531477): Cetuximab / vemurafenib combination therapy (Q44732143): combination therapy (Q1304270)
- BRAF V600 (Q28531477): vemurafenib / cobimetinib fumarate combination therapy (Q44844037): combination therapy (Q1304270)
- BRAF V600 (Q28531477): Cetuximab / encorafenib combination therapy (Q56240617): combination therapy (Q1304270)
- BRAF V600 (Q28531477): Dabrafenib / Trametinib combination therapy (Q38160427): combination therapy (Q1304270)
- BRAF V600 (Q28531477): Dabrafenib / Trametinib combination therapy (Q38160427): combination therapy (Q1304270)
- BRAF V600 (Q28531477): vemurafenib / cobimetinib fumarate combination therapy (Q44844037): combination therapy (Q1304270)
- BRAF V600 (Q28531477): vemurafenib / cobimetinib fumarate combination therapy (Q44844037): combination therapy (Q1304270)
- BRAF V600 (Q28531477): Dabrafenib / Trametinib combination therapy (Q38160427): combination therapy (Q1304270)
- BRAF V600 (Q28531477): binimetinib / encorafenib combination therapy (Q79414223): combination therapy (Q1304270)
- MTOR E2014K and E2419K (Q28532460): Everolimus / Pazopanib combination therapy (Q38160418): combination therapy (Q1304270)
- RB1 MUTATION (Q28546502): chemotherapy (Q974135): treatment of cancer (Q2575340), chemiotherapy (Q3252988)
- FGFR3 Mutation (Q29938048): cisplatin / gemcitabine combination therapy (Q50092436): combination therapy (Q1304270)
- ERBB2 Overexpression (Q29938315): gemcitabine / Trastuzumab combination therapy (Q58647120): combination therapy (Q1304270)
- ERBB2 Overexpression (Q29938315): Trastuzumab / paclitaxel combination therapy (Q58647123): combination therapy (Q1304270)
- ERBB2 Overexpression (Q29938315): capecitabine / Trastuzumab combination therapy (Q58645282): combination therapy (Q1304270)
- KRAS A146T (Q29938362): selumetinib / dactolisib combination therapy (Q44738723): combination therapy (Q1304270)
- TP53 Y220C (Q29938384): etoposide / mitomycin / cisplatin combination therapy (Q60242592): combination therapy (Q1304270)
- RRM1 Underexpression (Q29938752): cisplatin / gemcitabine combination therapy (Q50092436): combination therapy (Q1304270)
- RRM1 Underexpression (Q29938752): carboplatin / gemcitabine combination therapy (Q111398831): combination therapy (Q1304270)
- FLT3 D835V (Q29938817): sunitinib / daunorubicin combination therapy (Q44844341): combination therapy (Q1304270)
- FLT3 D835V (Q29938817): cytarabine / sunitinib combination therapy (Q44844344): combination therapy (Q1304270)
- MYC Overexpression (Q32949496): prexasertib / cisplatin / olaparib combination therapy (Q46738614): combination therapy (Q1304270)
- TP53 Overexpression (Q32964718): etoposide / mitomycin / cisplatin combination therapy (Q60242592): combination therapy (Q1304270)
- CHEK1 Overexpression (Q32965657): prexasertib / cisplatin / olaparib combination therapy (Q46738614): combination therapy (Q1304270)
- chr7:g.140453136A>T (BRAF:p.V600E) (Q42302375): Vemurafenib / Cobimetinib combination therapy (Q38160422): combination therapy (Q1304270)
- chr7:g.140453136A>T (BRAF:p.V600E) (Q42302375): Dabrafenib / Trametinib combination therapy (Q38160427): combination therapy (Q1304270)
- chr7:g.140453136A>T (BRAF:p.V600E) (Q42302375): Dabrafenib / Trametinib combination therapy (Q38160427): combination therapy (Q1304270)
- RAD50 L1237F (Q44844631): azd-7762 / irinotecan combination therapy (Q44844629): combination therapy (Q1304270)
- BRAF G466V (Q50092868): irinotecan / Panitumumab combination therapy (Q79419142): combination therapy (Q1304270)
- BAP1 ALTERNATIVE TRANSCRIPT (ATI) (Q56240987): apitolisib / olaparib combination therapy (Q79419133): combination therapy (Q1304270)
- FGFR3 Mutations (Q79419509): cisplatin / gemcitabine combination therapy (Q50092436): combination therapy (Q1304270)
- BRCA2 K3326* (Q98713516): temozolomide / olaparib combination therapy (Q98713515): combination therapy (Q1304270)
- ERCC1 Underexpression (Q111398942): carboplatin / gemcitabine combination therapy (Q111398831): combination therapy (Q1304270)
- IGF1R Overexpression (Q111399004): metformin / exemestane combination therapy (Q111399003): combination therapy (Q1304270)
Types statistics
[edit]
"Mandatory Qualifiers" violations
[edit]Violations count: 0
"Mandatory Qualifiers" violations
[edit]Violations count: 63
- ABL1 BCR::ABL E255K (Q27906817): rating (P4271)
- ABL1 BCR::ABL E255K (Q27906817): rating (P4271)
- ABL1 BCR::ABL E255K (Q27906817): rating (P4271)
- ABL1 BCR::ABL E255K (Q27906817): rating (P4271)
- RET C634W (Q27919564): rating (P4271)
- RET C634W (Q27919564): rating (P4271)
- ALK EML4::ALK G1269A (Q28371262): rating (P4271)
- ALK EML4::ALK G1269A (Q28371262): rating (P4271)
- ABL1 BCR::ABL F359V (Q29938345): rating (P4271)
- ABL1 BCR::ABL F359V (Q29938345): rating (P4271)
- ABL1 BCR::ABL F359V (Q29938345): rating (P4271)
- ABL1 BCR::ABL F359V (Q29938345): rating (P4271)
- ABL1 BCR::ABL Y253H (Q29938515): rating (P4271)
- ABL1 BCR::ABL Y253H (Q29938515): rating (P4271)
- ABL1 BCR::ABL Y253F (Q29938516): rating (P4271)
- ABL1 BCR::ABL Y253F (Q29938516): rating (P4271)
- ABL1 BCR::ABL Y253F (Q29938516): rating (P4271)
- ABL1 BCR::ABL H396R (Q29938523): rating (P4271)
- ABL1 BCR::ABL H396R (Q29938523): rating (P4271)
- ABL1 BCR::ABL E255V (Q29938702): rating (P4271)
- ABL1 BCR::ABL E255V (Q29938702): rating (P4271)
- ABL1 BCR::ABL E255V (Q29938702): rating (P4271)
- ABL1 BCR::ABL E255V (Q29938702): rating (P4271)
- ABL1 BCR::ABL E292V (Q29938706): rating (P4271)
- ABL1 BCR::ABL F359C (Q29938707): rating (P4271)
- ABL1 BCR::ABL F359C (Q29938707): rating (P4271)
- ABL1 BCR::ABL L384M (Q29938714): rating (P4271)
- ABL1 BCR::ABL L384M (Q29938714): rating (P4271)
- ABL1 V289I (Q32965306): rating (P4271)
- ABL1 Y342H (Q32965310): rating (P4271)
- ABL1 BCR::ABL V379I (Q32965324): rating (P4271)
- ABL1 Y393C (Q32965330): rating (P4271)
- chr9:g.133748282A>G (ABL1:p.T315A) (Q38105235): rating (P4271)
- chr9:g.133748282A>G (ABL1:p.T315A) (Q38105235): rating (P4271)
- chr9:g.133748288T>G (ABL1:p.F317V) (Q38152931): rating (P4271)
- chr9:g.133748288T>G (ABL1:p.F317V) (Q38152931): rating (P4271)
- chr9:g.133748288T>A (ABL1:p.F317I) (Q38152933): rating (P4271)
- chr9:g.133748288T>A (ABL1:p.F317I) (Q38152933): rating (P4271)
- chr9:g.133748289T>G (ABL1:p.F317C) (Q38152934): rating (P4271)
- chr9:g.133748289T>G (ABL1:p.F317C) (Q38152934): rating (P4271)
- chr9:g.133748414T>A (ABL1:p.F359I) (Q38153149): rating (P4271)
- chr9:g.133748414T>A (ABL1:p.F359I) (Q38153149): rating (P4271)
- chr7:g.140453137C>T (BRAF:p.V600M) (Q38153304): rating (P4271)
- chr7:g.140453136A>C (BRAF:p.V600G) (Q38153306): rating (P4271)
- chr7:g.55259524T>A (EGFR:p.L861Q) (Q38153310): rating (P4271)
- chr7:g.55259524T>A (EGFR:p.L861Q) (Q38153310): rating (P4271)
- chr7:g.55241707G>T (EGFR:p.G719C) (Q38153312): rating (P4271)
- chr7:g.55241707G>T (EGFR:p.G719C) (Q38153312): rating (P4271)
- chr7:g.55241708G>A (EGFR:p.G719D) (Q38153314): rating (P4271)
- chr7:g.55241708G>A (EGFR:p.G719D) (Q38153314): rating (P4271)
- chr7:g.55242470T>C (EGFR:p.L747S) (Q38153315): rating (P4271)
- chr7:g.55242470T>C (EGFR:p.L747S) (Q38153315): rating (P4271)
- chr7:g.55259524T>C (EGFR:p.L861P) (Q38153317): rating (P4271)
- chr7:g.55259524T>C (EGFR:p.L861P) (Q38153317): rating (P4271)
- chr7:g.55259524T>G (EGFR:p.L861R) (Q38153318): rating (P4271)
- chr7:g.55259524T>G (EGFR:p.L861R) (Q38153318): rating (P4271)
- chr7:g.140453136A>T (BRAF:p.V600E) (Q42302375): rating (P4271)
- chr7:g.140453136A>T (BRAF:p.V600E) (Q42302375): rating (P4271)
- chr7:g.140453136A>T (BRAF:p.V600E) (Q42302375): rating (P4271)
- chr7:g.140453136A>T (BRAF:p.V600E) (Q42302375): rating (P4271)
- chr7:g.140453136A>T (BRAF:p.V600E) (Q42302375): rating (P4271)
- chr7:g.140453136A>T (BRAF:p.V600E) (Q42302375): rating (P4271)
- chr7:g.140453136A>T (BRAF:p.V600E) (Q42302375): rating (P4271)
"Mandatory Qualifiers" violations
[edit]Violations count: 20
- ABL1 BCR::ABL E255K (Q27906817): determination method or standard (P459)
- ABL1 BCR::ABL E255K (Q27906817): determination method or standard (P459)
- RET C634W (Q27919564): determination method or standard (P459)
- ALK EML4::ALK G1269A (Q28371262): determination method or standard (P459)
- ABL1 BCR::ABL F359V (Q29938345): determination method or standard (P459)
- ABL1 BCR::ABL F359V (Q29938345): determination method or standard (P459)
- ABL1 BCR::ABL Y253F (Q29938516): determination method or standard (P459)
- ABL1 BCR::ABL Y253F (Q29938516): determination method or standard (P459)
- ABL1 BCR::ABL Y253F (Q29938516): determination method or standard (P459)
- ABL1 BCR::ABL H396R (Q29938523): determination method or standard (P459)
- ABL1 BCR::ABL H396R (Q29938523): determination method or standard (P459)
- ABL1 BCR::ABL E255V (Q29938702): determination method or standard (P459)
- ABL1 BCR::ABL E255V (Q29938702): determination method or standard (P459)
- ABL1 BCR::ABL E292V (Q29938706): determination method or standard (P459)
- ABL1 BCR::ABL L384M (Q29938714): determination method or standard (P459)
- ABL1 BCR::ABL L384M (Q29938714): determination method or standard (P459)
- ABL1 V289I (Q32965306): determination method or standard (P459)
- ABL1 Y342H (Q32965310): determination method or standard (P459)
- ABL1 BCR::ABL V379I (Q32965324): determination method or standard (P459)
- ABL1 Y393C (Q32965330): determination method or standard (P459)